

**Ohio Department of Medicaid (ODM)  
Drug Utilization Review (DUR) Board  
Quarterly Meeting  
September 16, 2014**

The quarterly meeting of the ODM DUR Board was called to order at 11:59 AM in Room 1948 Riffe Center, 77 S. High Street, Columbus, Ohio. Thomas Gretter, MD, presided. The following Board members were present:

David Brookover, RPh,  
Michael Farrell, MD  
Thomas Gretter, MD, Chair  
Robert Kubasak, RPh  
Kevin Mitchell, RPh  
J. Layne Moore, MD  
Lenard Presutti, DO  
Donald Sullivan, RPh, PhD

Also present were Pam Heaton, RPh, PhD and Robert Cluxton RPh, PharmD, from the University Of Cincinnati College Of Pharmacy; Margaret Scott, RPh, DUR Administrator; Jill Griffith, RPh, PharmD, DUR Director; Alison Barnett; Mike Howcroft, RPh; and Patti Nussle, RPh, from ODM. Approximately 7 observers were present, most representing pharmaceutical manufacturers.

Reading, Correction & Approval of Previous Minutes:

The May 20th, 2014, DUR Board minutes were approved. (1<sup>st</sup> D. Brookover, 2<sup>nd</sup> L. Moore).

Unfinished Business:

M. Scott reviewed reports on antipsychotic use in long-term care and psychotropic use in children. M. Scott introduced new pharmacist Patti Nussle, RPh, and new project manager Alison Barnett. Regarding the Governor's Cabinet Opiate Action Team, the state is working to increase naloxone availability to first responders (police officers, emergency medical services, emergency medical technicians). Preventive doses of naloxone will be available to high risk patients through the pharmacy benefit. The Board discussed legal changes for dispensing opiates. The first change requires informed consent before prescribing controlled substances to patients less than 18 years of age. The second change moves hydrocodone combination products from a Schedule III to a Schedule II status.

Health Plan Policy:

M. Scott announced that the new Preferred Drug List goes into effect on October 1<sup>st</sup> 2014. The HIV Antiretroviral category goes into effect on November 1<sup>st</sup> 2014.

DUR Committee Report:

J. Griffith announced that the June DUR Committee reviewed the profiles of 86 patients with a daily morphine equivalent dose (MED) greater than or equal to 500. The committee did not meet in July or August. The September committee continued to focus on those patients with MED greater than or equal to 500. Going forward, each pharmacist on the DUR committee will be assigned a specific group of

patients to follow and review monthly. Patients will be added to and removed from the watch list as clinically indicated and interventions performed as necessary. The DUR Annual report is due to CMS September 30, 2014. J. Griffith will share the report with the Board in November. J. Griffith also announced that 18 percent of responses are back on the concurrent insulin and sulfonylurea intervention mailed during July. 182 letters were mailed to prescribers. Reminder letters went out last week to those who have not returned their surveys. Overall, the feedback has been positive.

M. Scott requested the Board provide feedback on two potential DUR intervention topics. The first topic is concurrent stimulant and benzodiazepine use. The second topic is a drug cost reduction intervention to optimize once daily, flat priced drugs. The Board agreed that both topics should be evaluated.

Announcements:

The fourth quarter DUR Board meeting will be on November 18 at noon in the Riffe building on the 31st floor. Elections for chair and co-chair will occur during the November meeting. The Board scheduled the first quarter DUR Board meeting on February 17, 2015, and the second quarter meeting on May 19, 2015.

Adjournment:

T. Gretter adjourned the meeting at 12:41 PM

Respectfully submitted:

---

Jill RK Griffith BS, PharmD, DUR Program Director